Bavarian Nordic to Host Third Quarter 2022 Results Conference Call
November 02, 2022 12:30 ET | Bavarian Nordic A/S
COPENHAGEN, Denmark – November 2, 2022 - Bavarian Nordic A/S (OMX:  BAVA) will announce its 2022 third quarter results on Wednesday, November 9, 2022. The management of Bavarian Nordic will host...
Bavarian Nordic afholder telefonkonference i forbindelse med offentliggørelsen af regnskabet for tredje kvartal 2022
November 02, 2022 12:30 ET | Bavarian Nordic A/S
KØBENHAVN, 2. november 2022 – Bavarian Nordic A/S (OMX: BAVA) offentliggør regnskab for tredje kvartal 2022 på onsdag den 9. november 2022. Samme dag kl. 14:00 dansk tid afholder selskabets...
Bavarian Nordic’s COVID-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial
October 17, 2022 02:46 ET | Bavarian Nordic A/S
Six months post the booster vaccination with ABNCoV2, the neutralization antibody titers against Wuhan and the Omicron variant remained high and at levels associated with a greater than 90% efficacy. ...
Bavarian Nordics COVID-19 boostervaccinekandidat viser vedvarende antistofresponser 6 måneder efter vaccination i fase 2-forsøg
October 17, 2022 02:46 ET | Bavarian Nordic A/S
6 måneder efter boostervaccination med ABNCoV2 forblev koncentrationen af neutraliserede antistoffer mod Wuhan og omikron på høje niveauer, der er associeret med mere end 90% effektivitet. KØBENHAVN,...
Bavarian Nordic Enters Agreement with Switzerland on the Supply of Smallpox and Monkeypox Vaccine
October 14, 2022 07:30 ET | Bavarian Nordic A/S
Switzerland has ordered 100,000 doses of smallpox and monkeypox vaccine with deliveries starting imminentlyBavarian Nordic will seek regulatory approval of the vaccine with Swissmedic, the Swiss...
Bavarian Nordic indgår aftale med Schweiz om levering af koppe- og abekoppevacciner
October 14, 2022 07:30 ET | Bavarian Nordic A/S
Schweiz har bestilt 100.000 doser koppe- og abekoppevaccine med omgående start af leverancerBavarian Nordic vil søge regulatorisk godkendelse af vaccinen hos det schweiziske lægemiddelagentur,...
Bavarian Nordic Enters Agreement with Country in Latin America on the Supply of Monkeypox Vaccines
October 03, 2022 01:30 ET | Bavarian Nordic A/S
First country in Latin America to sign a bilateral supply agreement thus expanding access to the monkeypox vaccine beyond the availability of vaccines through PAHOAdditional supply agreement also...
Bavarian Nordic indgår aftale med land i Latinamerika om levering af abekoppevacciner
October 03, 2022 01:30 ET | Bavarian Nordic A/S
Første land i Latinamerika, som indgår bilateral leveringskontrakt, hvilket øger adgangen til abekoppevaccinen ud over de vacciner, der stilles til rådighed via PAHOYderligere leveringskontrakt er...
Luc Debruyne Appointed as Observer to the Board of Directors of Bavarian Nordic
September 20, 2022 07:01 ET | Bavarian Nordic A/S
COPENHAGEN, Denmark, September 20, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the board of directors has appointed Luc Debruyne as an observer to the board with the intent to nominate...
Luc Debruyne udnævnt til observatør i bestyrelsen for Bavarian Nordic
September 20, 2022 07:01 ET | Bavarian Nordic A/S
KØBENHAVN, Danmark, 20. september 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at bestyrelsen har udnævnt Luc Debruyne til observatør i bestyrelsen med hensigt at opstille ham til valg til...